Humacyte, Inc. SEC filings HUMA
Humacyte, Inc. has 504 filings in SEC EDGAR's recent list, going back to Aug 4, 2020. Its latest annual report, Form 10-K, was filed on Mar 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 28, 2026 (officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 25-NSE | Delisting notice | Aug 25, 2026 | — |
| EFFECT | Filing | Sep 22, 2025 | — |
| CORRESP | Letter to the SEC | Sep 18, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 17, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 13, 2024 | — |
| CORRESP | Letter to the SEC | Aug 6, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 23, 2024 | — |
| EFFECT | Filing | Jun 21, 2023 | — |
| CORRESP | Letter to the SEC | Jun 16, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 15, 2023 | — |
| EFFECT | Filing | Sep 14, 2022 | — |
| EFFECT | Filing | Sep 9, 2022 | — |
| EFFECT | Filing | Sep 9, 2022 | — |
| CORRESP | Letter to the SEC | Sep 7, 2022 | — |
| CORRESP | Letter to the SEC | Sep 7, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 7, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 7, 2022 | — |
| EFFECT | Filing | Mar 31, 2022 | — |
| EFFECT | Filing | Nov 24, 2021 | — |
| EFFECT | Filing | Oct 25, 2021 | — |
| CORRESP | Letter to the SEC | Oct 21, 2021 | — |
| UPLOAD | Letter from the SEC | Sep 21, 2021 | — |
| 25-NSE | Delisting notice | Aug 26, 2021 | — |
| 425 | Current report | Aug 17, 2021 | — |
| EFFECT | Filing | Aug 4, 2021 | — |
| 425 | Current report | Aug 4, 2021 | — |
| SEC STAFF LETTER | Filing | Aug 4, 2021 | — |
| CORRESP | Letter to the SEC | Aug 3, 2021 | — |
| CORRESP | Letter to the SEC | Aug 2, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 29, 2021 | — |
| CORRESP | Letter to the SEC | Jul 23, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 15, 2021 | — |
| CORRESP | Letter to the SEC | Jun 30, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 24, 2021 | — |
| CORRESP | Letter to the SEC | Jun 11, 2021 | — |
| 425 | Current report | Jun 7, 2021 | — |
| 425 | Current report | May 26, 2021 | — |
| 425 | Form 8-k | May 21, 2021 | — |
| 425 | Current report | May 20, 2021 | — |
| 425 | Current report | May 13, 2021 | — |
| 425 | Current report | May 6, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 22, 2021 | — |
| 425 | Current report | Apr 21, 2021 | — |
| 425 | Current report | Apr 14, 2021 | — |
| SEC STAFF LETTER | Filing | Apr 13, 2021 | — |
| 425 | Current report | Mar 5, 2021 | — |
| 425 | Current report | Feb 17, 2021 | — |
| 425 | Current report | Feb 17, 2021 | — |
| EFFECT | Filing | Sep 17, 2020 | — |
| CERT | Filing | Sep 17, 2020 | — |
| 8-A12B | For registration of certain classes | Sep 17, 2020 | — |
Showing 51 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- HUMA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Durham, NC
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1818382
- Former names
- Alpha Healthcare Acquisition Corp. (until Aug 26, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.